• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

JAK inhibitors

photo of a pair of binoculars perched on a rock aimed at the rising sun
Favicon Fierce Pharma

New Incyte CEO takes 'fresh look' at business, outlines BD plan

Incyte will look for “derisked pre-revenue or revenue-stage opportunities,” new CEO Bill Meury said.
Angus Liu Aug 4, 2025 11:16am
target reach ladder climb meet win beat competition

Soterios looks to ph. 3 after win for alopecia areata cream

May 30, 2024 8:14am
An arrow incrementally going up stairs before pointing straight up Blue background

Incyte's oral Dupixent rival hits in midphase skin disease trial

Mar 11, 2024 7:16am
Takeda

How Takeda beat the rest of the industry to snag Nimbus' TYK2

Jan 11, 2024 10:30am
layoff layoffs staff

Aclaris lays off 46%, resurrects zunsemetinib for cancer

Dec 20, 2023 6:09am
Directions

ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med

Dec 11, 2023 4:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings